<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619372</url>
  </required_header>
  <id_info>
    <org_study_id>YI002-HMO-CTIL</org_study_id>
    <secondary_id>Protocol No. 01-300</secondary_id>
    <nct_id>NCT00619372</nct_id>
  </id_info>
  <brief_title>Oral OKT3 in Combination With Beta-D-Glucosylceramide</brief_title>
  <official_title>Administration of Anti-CD3 (OKT3) in Combination With Beta-D-Glucosylceramide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to evaluate the safety of oral administration of the study&#xD;
      drug anti CD3 (OKT3) in combination with β-D glucosylceramide [GC] .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti CD3 (OKT3): Is an approved drug for intravenous use in the treatment of solid organ&#xD;
      transplantation. Preliminary data suggest that the oral administration of OKT3 in low dosages&#xD;
      can exert an immune modulatory effect via activation of regulatory T lymphocytes.&#xD;
&#xD;
      β-D glucosylceramide [GC]: Is approved for oral administration and is currently being tested&#xD;
      in three clinical trials. Recent data suggested that it can serve as an immunological&#xD;
      adjuvant in various clinical settings and to augment the immune response via activation of&#xD;
      regulatory T cells.&#xD;
&#xD;
      This clinical trial has been designed to assess the safety of oral administration of OKT3&#xD;
      with and without co-administration of GC in healthy subjects. The use of two potential&#xD;
      activators of regulatory T cells, may exert an additive effect, augmenting the systemic&#xD;
      immune modulatory effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the safety of oral administration of OKT3 with and without GC in healthy volunteers by monitoring the subjects for adverse events and by interpreting the results of the various laboratory tests and the subjects' diaries.</measure>
    <time_frame>January-April</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of 5 consecutive doses of oral OKT3 with and with out GC and the dose escalation effect in healthy volunteers.</measure>
    <time_frame>January-April</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose OKT3 with GC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose OKT3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid OKT3 dose with GC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose OKT3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose OKT3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT3</intervention_name>
    <description>0.2 mg OKT3, PO (in the mouth) on day 1 through 5.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>OKT3, Monoclonal anti CD3.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT3, GC</intervention_name>
    <description>0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5</description>
    <arm_group_label>B</arm_group_label>
    <other_name>OKT3, antiCD3</other_name>
    <other_name>GC, glucosylceramide, beta glucosylceramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT3</intervention_name>
    <description>1 mg OKT3, PO (in the mouth) on day 1 through 5</description>
    <arm_group_label>C</arm_group_label>
    <other_name>OKT3, antiCD3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT3, GC</intervention_name>
    <description>1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5</description>
    <arm_group_label>D</arm_group_label>
    <other_name>OKT3, antiCD3</other_name>
    <other_name>GC, glucosylceramide, beta glucosylceramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT3</intervention_name>
    <description>5 mg OKT3, PO (in the mouth) on day 1 through 5</description>
    <arm_group_label>E</arm_group_label>
    <other_name>OKT3, anti-CD3</other_name>
    <other_name>GC, glucosylceramide, beta-glucosylceramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC</intervention_name>
    <description>7.5 mg GC, PO (in the mouth) on day 1 through 5</description>
    <arm_group_label>F</arm_group_label>
    <other_name>GC, glucosylceramide, beta glucosylceramide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have completed the informed consent process culminating with written&#xD;
             informed consent by the subject.&#xD;
&#xD;
          -  Men and women &gt; 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have undergone surgery within the last 3 months.&#xD;
&#xD;
          -  Subjects who have had a prior colostomy, ileostomy, or colectomy with ileorectal&#xD;
             anastamosis.&#xD;
&#xD;
          -  Subjects presenting with, or who have a history of, persistent intestinal obstruction,&#xD;
             bowel perforation, uncontrolled bleeding or abdominal abscess or infection, toxic&#xD;
             megacolon.&#xD;
&#xD;
          -  Subjects with a clinically significant infectious, immune mediated or malignant&#xD;
             disease&#xD;
&#xD;
          -  Subjects who are receiving an elemental diet or parenteral nutrition.&#xD;
&#xD;
          -  Subjects who have been treated with any time of immune modulatory drug including&#xD;
             steroids or NSAID within the last 4 weeks.&#xD;
&#xD;
          -  Subjects who have received either methotrexate or cyclosporine or anti TNF alpha&#xD;
             (infliximab, Remicade), anti-integrin (namixilab) or who have participated in any&#xD;
             other clinical trial within the last 3 months.&#xD;
&#xD;
          -  Subjects with a history of coagulopathy.&#xD;
&#xD;
          -  Women with childbearing potential unless surgically sterile or using adequate&#xD;
             contraception (either IUD, oral or Depo -provera contraceptive, or barrier plus&#xD;
             spermicide); pregnant or breastfeeding mothers.&#xD;
&#xD;
          -  Subjects who will be unavailable for the duration of the trial, are likely to be&#xD;
             non¬compliant with the protocol, or who are felt to be unsuitable by the investigator&#xD;
             for any other reason.&#xD;
&#xD;
          -  Subjects who are HIV positive&#xD;
&#xD;
          -  Subjects who are HBsAg positive&#xD;
&#xD;
          -  Subjects who are HCV positive&#xD;
&#xD;
          -  Subjects with active CMV&#xD;
&#xD;
          -  Subjects who demonstrate a positive PPD&#xD;
&#xD;
          -  Subjects with anemia (Hb &lt;10.5 gm/dl)&#xD;
&#xD;
          -  Subjects with thrombocytopenia (platelets &lt;100K/microliter)&#xD;
&#xD;
          -  Subjects with lymphopenia (absolute lymphocyte count &lt;0.7)&#xD;
&#xD;
          -  Subjects with IgG anti-cardiolipin antibody &gt;16 IU&#xD;
&#xD;
          -  Prior exposure to OKT3&#xD;
&#xD;
          -  Known sensitivity to any ingredients in the study drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehud Zigmond, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Neurologic Diseases, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>February 10, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ehud Zigmond, M.D.</name_title>
    <organization>Hadassah University Hospital</organization>
  </responsible_party>
  <keyword>OKT3</keyword>
  <keyword>beta-glucosylceramide</keyword>
  <keyword>oral tolerance</keyword>
  <keyword>anti-CD3</keyword>
  <keyword>Safety assessment and healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

